Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — E&P Healthcare Conference 2026
29 slides from Amplia Therapeutics's conference presentation, Sep 16, 2026
Slide 1: Amplia Presents at E&P Healthcare Conference 2026
16 SEPTEMBER 2026 For personal use only ASX RELEASE AMPLIA PRESENTS AT E&P HEALTHCARE CONFERENCE 2026 Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), is pleased to announce that CEO and Managing Director Dr Chris Burns will be presenting at the E&P Healthcare conference in
Slide 2: For personal use only
to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib wi
Slide 3: Targeting pancreatic cancer and beyond
For personal use only Targeting pancreatic cancer and beyond SEPTEMBER 2026 ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF 1
Slide 4: Disclaimer
2 Disclaimer For personal use only This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN Forward-looking statements are based on the Company’s good faith assumptions as to the financial 165 160 841 and its subsidiaries (the Company or Amplia) which is cu
Slide 5: The FAK Opportunity
3 The FAK Opportunity A large and unmet clinical need exists in cancers where FAK contributes to disease For personal use only Lead program Pancreatic Cancer Ovarian Cancer kRAS Combinations US$32b lung cancer market3 US$2.5b market1 US$3.9b market2 US$19b CRC market4 Exciting data from ACCENT Trial
Slide 6: Targeting fibrosis and resistance
4 Targeting fibrosis and resistance Narmafotinib breaks down fibrosis surrounding the tumour, and For personal use only blocks survival and resistance pathways in cancer cells Chemotherapy NARMAFOTINIB FAK drives a dense fibrous Narmafotinib acts to reduce Chemotherapy can now matrix that surrounds
Slide 7: ACCENT Trial in pancreatic cancer
For personal use only ACCENT Trial in pancreatic cancer Excellent tolerability and responses observed 5
Slide 8: ACCENT Pancreatic Cancer Trial
6 ACCENT Pancreatic Cancer Trial Phase 1b/2a clinical trial in Australia and South Korea For personal use only Narmafotinib plus standard-of-care Narmafotinib Chemotherapy chemotherapy Newly diagnosed patients Metastatic disease Taken orally in 64 patients at top dose narmafotinib days preceding Thr
Slide 9: ACCENT Pancreatic Cancer Trial
7 ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine / Abraxane in first-line advanced pancreatic cancer For personal use only 7.8% 70% 11.1 months months No Extra Burden Complete Disease Median Safety & response rate control rate overall survival tolerability Superior to chemo alone Chemo al
Slide 10: ACCENT Pancreatic Cancer Trial
8 ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine / abraxane in first-line advanced pancreatic cancer For personal use only Deep and sustained tumour shrinkage OS related to Response White circles indicate patients alive at March review
Slide 11: ACCENT registration pathway
9 ACCENT registration pathway A three-part registration pathway designed around FDA feedback For personal use only Underway Final planning Final planning ACCENT Mini ACCENT Reg - P2b ACCENT Reg - P3 Daily dosing at two dose levels Builds on ACCENT Mini data to Pivotal registrational study Gemcitabin
Slide 12: The Pancreatic Cancer treatment landscape
The Pancreatic Cancer treatment landscape New developments changing treatment journey For personal use only Chemotherapy predicted to remain a significant Market Size (7 MM) component of treatment paradigm FOLFIRINOX and gemcitabine+Abraxane are main chemotherapy options Growing awareness that gemci
Slide 13: kRAS Inhibitors
For personal use only kRAS Inhibitors An exciting new class of anti-cancer therapies - ideally suited for FAK inhibitor combination 11
Slide 14: kRAS mutations prevalent in cancer
12 kRAS mutations prevalent in cancer Significant cancer driver in multiple indications For personal use only 100 Clinical studies demonstrating 80 good activity % kRAS Prevalence 60 Resistance and tolerability significantly limits long term 40 treatment 20 80+ kRAS drugs now in clinical 0 developme
Slide 15: Significant competition in development
13 Significant competition in development Combinations critical to development strategy For personal use only Chugai Kestrel G12C G12D Lilly Roche pan Amgen Erasca Pfizer BridgeBio Genhouse Alterome Qilu Frontier Astellas Verastem RevMed RevMed Astellas AZ RevMed HuyaBio SJ Pharma Hansoh Bayer Innov
Slide 16: The Opportunity Ahead
14 The Opportunity Ahead Combinations critical to development strategy For personal use only
Slide 17: Narmafotinib and kRAS inhibition
15 Narmafotinib and kRAS inhibition Overcoming acquired resistance to kRAS inhibitors For personal use only FAK signaling is an escape mechanism to blockade of RAS pathway Growing evidence for clinical benefit of FAK + kRAS inhibition Approval of defactinib + avutometinib (Co-Pack) in kRAS mutant LG
Slide 18: Lilly Collaboration - Background
16 Lilly Collaboration - Background Enhancing efficacy for next-generation kRAS G12C inhibitor For personal use only FDA-approved G12C targeted drugs - first Drug Trial Setting mPFS mOS ORR generation Adagrasib (BMS); Sotorasib (Amgen) Adagrasib KRYSTAL-12 Phase 3 5.5 mos Immature 31.9% 2L+ NSCLC Cl
Slide 19: Lilly Collaboration - Detail
17 Lilly Collaboration - Detail Enhancing efficacy for next-generation kRAS G12C inhibitor For personal use only Previously treated KRAS G12C-mutant advanced or Phase 1b metastatic NSCLC Olomorasib (100 mg, BID) Phase 1b/2b study Narmafotinib Narmafotinib Narmafotinib (200 mg, QD) (400 mg, QD) (600
Slide 20: Lilly Collaboration
Lilly Collaboration Important validation of the potential of our science For personal use only Eli Lilly and Co. Lilly Oncology Pipeline Market Cap US$1.1 T Marketed oncology drugs Verzenio (abemaciclib) Jaypirca (pirtobrutinib) Retevmo (selpercatinib) A deep pipeline of small molecules drugs, radio
Slide 21: PRROSE Trial in ovarian cancer
For personal use only PRROSE Trial in ovarian cancer Building on promising preclinical and literature data 19
Slide 22: Ovarian Cancer
20 Ovarian Cancer 70% For personal use only of patients are diagnosed at advanced stage where 5-year survival is 20% 20% of patients will be resistant or develop resistance during initial treatment ~50% of an ovarian tumour is fibrotic - a key driver of drug resistance
Slide 23: PRROSE Trial
21 PRROSE Trial For personal use only The study is an investigator-initiated clinical trial led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated through ANZGOG ~20 Patients Treatment Surgery Endpoints HGSOC Narmafotinib + interval debulking Safety, surgical elig
Slide 24: Development Timeline
Development Timeline For personal use only 2026 2027 2028 2029 ACCENT ACCENT-mini safety data ACCENT-reg FDA Meeting FDA Meeting PRROSE 22
Slide 25: Development Timeline
Development Timeline For personal use only 2026 2027 2028 2029 ACCENT ACCENT-mini safety data ACCENT-reg FDA Meeting FDA Meeting Olomorasib combination KRASi combination 2 PRROSE 23
Slide 26: Development Timeline
24 Development Timeline For personal use only 2026 2027 2028 2029 ACCENT ACCENT-mini safety data ACCENT-reg FDA Meeting FDA Meeting KRASi arm Olomorasib combination KRASi combination 2 PRROSE
Slide 27: Corporate Summary
Corporate Summary For personal use only ASX:ATX | OTCQB:INNMF 12 month share price chart Share price A$0.12 (15-Sep-2026) Shares on 513.3M issue Market cap A$61.60M (15-Sep-2026) Cash at hand A$24.0M (30-Jun-2026) Platinum Investment Management Ltd Substantial Acorn Capital Ltd Shareholders Blueflag
Slide 28: Board and Management
26 Board and Management World-class expertise For personal use only SENIOR MANAGEMENT BOARD Rhiannon Jones PhD GAICD COO Jason Lickliter MBBS FRACP CMO Jane Bell AM Warwick Tong Robert Peach Brett Carter Chris Burns LLB LLM (Lond) FAICD MB ChB MPP GAICD PhD BSc MBA GAICD PhD GAICD FAHMS Chair Direct
Slide 29: Thank You
For personal use only Thank You Chris Burns PhD GAICD FAHMS CEO and MD chris@ampliatx.com Amplia Therapeutics Limited ASX: ATX | OTCQB: INNMF info@ampliatx.com ampliatx.com